Data Sharing and Analytics for Oncology Research Launched
Project Data Sphere, an independent not-for-profit initiative, has launched a data sharing platform
Project Data Sphere (PDS), an independent not-for-profit initiative has launched a data sharing platform that has been specifically designed to provide one place where the cancer community can broadly share, integrate and analyze historical patient level, comparator arm data from academic and industry phase III cancer clinical trials. The initiative addressed prior obstacles to clinical trial data sharing by working with leading legal and privacy experts, as well as clinicians, commercial institutions and patient representatives to build an optimal framework to share data responsibly.
Initial data sets of de-identified, patient level data, have been provided by AstraZeneca, Bayer, Celgene, Janssen Research and Development, an affiliate of Johnson & Johnson, Memorial Sloan Kettering Cancer Center, Pfizer, and Sanofi US. PDS is currently working with these and other organizations, including the Alliance for Clinical Trials in Oncology (sponsored by the National Cancer Institute), Amgen, and Quintiles to provide additional cancer data sets.
The Project Data Sphere platform was developed by SAS, an industry leader in data security and analytics. State of the art analytic tools are available on demand to registered users within the platform.
Read the full release here.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
